Caas Capital Management LP Biocryst Pharmaceuticals Inc Transaction History
Caas Capital Management LP
- $836 Million
- Q3 2024
A detailed history of Caas Capital Management LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Caas Capital Management LP holds 25,000 shares of BCRX stock, worth $180,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,000Holding current value
$180,250% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BCRX
# of Institutions
279Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$146 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$144 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$85.5 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$65.5 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$63.8 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.34B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...